Amgen, Daiichi Sankyo announce exclusive agreement to commercialize biosimilars in Japan

Amgen and Daiichi Sankyo Company Limited have announced their exclusive agreement to commercialize nine biosimilars in Japan, according to a press release.

Under the agreement, Amgen will reportedly remain in charge of the development and manufacturing of the biosimilars and Daiichi Sankyo will reportedly file for marketing approval and be in charge of the distribution and commercialization in Japan. According to the release, Amgen will only have limited rights to co-promote the biosimilars.

“Amgen is excited to collaborate with Daiichi Sankyo as we seek to drive adoption and build confidence in biosimilars as a means of enhancing patient access to more affordable therapeutic options worldwide,” Scott Foraker, vice president and general manager of biosimilars at Amgen, said in the release.

According to the release, Amgen will continue to have distribution and commercialization rights for biosimilar programs outside of Japan. No financial terms were disclosed regarding the agreement.

 

Reference:

www.amgenbiosimilars.com

 

Amgen and Daiichi Sankyo Company Limited have announced their exclusive agreement to commercialize nine biosimilars in Japan, according to a press release.

Under the agreement, Amgen will reportedly remain in charge of the development and manufacturing of the biosimilars and Daiichi Sankyo will reportedly file for marketing approval and be in charge of the distribution and commercialization in Japan. According to the release, Amgen will only have limited rights to co-promote the biosimilars.

“Amgen is excited to collaborate with Daiichi Sankyo as we seek to drive adoption and build confidence in biosimilars as a means of enhancing patient access to more affordable therapeutic options worldwide,” Scott Foraker, vice president and general manager of biosimilars at Amgen, said in the release.

According to the release, Amgen will continue to have distribution and commercialization rights for biosimilar programs outside of Japan. No financial terms were disclosed regarding the agreement.

 

Reference:

www.amgenbiosimilars.com

 

    See more from Biosimilars in the United States: Current Status and Future Implications